¹²⁵I-Radiopharmaceutical

¹²⁵I-radiopharmaceuticals are compounds labeled with iodine-125, an isotope extensively used in medical imaging and therapeutic applications for targeting diseased tissues. At Alfa Cytology, we focus on researching and developing ¹²⁵I-radiopharmaceuticals, striving to enhance the effectiveness and precision of targeted tumor therapies through advanced iodine-125 labeling techniques.

Overview of ¹²⁵I Radiopharmaceuticals

Iodine-125 is a low-energy beta- and gamma-radiation source with a half-life of 59.4 days, making it ideal for tumor-targeted therapies, organ imaging, and various biological studies due to its moderate radioactivity duration in the body. Radiopharmaceuticals labeled with ¹²⁵I are specifically designed to bind to molecules or antibodies that target receptors or antigens on the surface of tumor cells, allowing for precise therapy and imaging. Compared to other radioisotopes, ¹²⁵I offers a lower radiation dose and extended applicability for prolonged imaging observations.

Fig.1 Chemical structures of [¹²⁵I]-labeled chalcone derivatives. (TESSE G, et al., 2024)

Common ¹²⁵I Targets

• Tumor Cell Surface Antigens

¹²⁵I-labeled monoclonal antibodies or small molecule drugs are frequently used to target specific antigens on tumor cell surfaces, such as HER2, EGFR, and PSMA. These targets enable precise tumor imaging and targeted therapies.

• Neuroendocrine Receptors

Certain ¹²⁵I-labeled peptide molecules can target receptors on neuroendocrine tumor cells, like the somatostatin receptor (SSTR). This targeting facilitates the diagnosis and treatment of neuroendocrine tumors.

• Immune Cell Receptors

¹²⁵I can bind to receptors on immune cells, aiding in the study of immune responses and cell function. ¹²⁵I-labeled antibodies enable quantitative analysis of these immune responses.

• Enzymes

Some ¹²⁵I-labeled molecules serve as substrates or inhibitors for specific enzymes, particularly those involved in key metabolic processes like proteases or kinases.

• Vascular Endothelial Cell Receptors

In early stages of diseases such as cancer or inflammation, ¹²⁵I-labeled molecules can target receptors on vascular endothelial cells, enabling vascular imaging and targeted therapies.

Our Services

Alfa Cytology is committed to advancing the development and optimization of ¹²⁵I-labeled radiopharmaceuticals to enhance the precision and efficacy of targeted tumor therapies. By innovating in radiopharmaceutical design, Alfa Cytology pushes forward the research of ¹²⁵I-based solutions for cancer treatment and molecular imaging applications, aiming to provide safer and more effective treatment options.

Preclinical Services for ¹²⁵I Radiopharmaceuticals

Alfa Cytology offers comprehensive development services for ¹²⁵I nuclear drugs and is dedicated to providing expert follow-up support to our clients. Our services encompass the entire preclinical experimental phase, ensuring that each development project progresses smoothly and achieves its desired outcomes.

Alfa Cytology has delivered ¹²⁵I nuclear drug development services to numerous clients, supported by an experienced team and state-of-the-art instrumentation. Our expertise ensures high-quality outcomes and innovative solutions. If your project encounters any challenges or requires specialized guidance, please feel free to contact us. We are eager to provide you with professional support and tailored assistance to meet your specific needs.

Reference

1. TESSE G, TOLOMEO A, DE FILIPPIS B, et al. Radiolabeled Probes from Derivatives of Natural Compounds Used in Nuclear Medicine [J]. Molecules (Basel, Switzerland), 2024, 29(17).

• ⁶⁸Ga-Radiopharmaceutical
• ¹⁸F-Radiopharmaceutical
• ⁸⁹Zr-Radiopharmaceutical
• ⁹⁹mTc-Radiopharmaceutical
• ¹²³I-Radiopharmaceutical
• ¹³¹I-Radiopharmaceutical
• ¹¹C-Radiopharmaceutical
• ¹⁴C-Radiopharmaceutical
• ¹⁷⁷Lu-Radiopharmaceutical
• ⁹⁰Y-Radiopharmaceutical
• ⁸⁹Sr-Radiopharmaceutical
• ²²⁵Ac-Radiopharmaceutical